Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014


#230793

102pages

Global Markets Direct

$ 2000

In Stock

Global Markets Directs, Hematopoietic Stem Cell Transplantation Pipeline Review, H2 2014, provides an overview of the Hematopoietic Stem Cell Transplantations therapeutic pipeline.

 

This report provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hematopoietic Stem Cell Transplantation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

 

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

 

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Hematopoietic Stem Cell Transplantation Overview 8

Therapeutics Development 9

Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview 9

Pipeline Products for Hematopoietic Stem Cell Transplantation - Comparative Analysis 10

Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies 11

Hematopoietic Stem Cell Transplantation - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Hematopoietic Stem Cell Transplantation - Products under Development by Companies 16

Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development 17

Actinium Pharmaceuticals, Inc. 17

Athersys, Inc. 18

BioLineRx, Ltd. 19

Celldex Therapeutics, Inc. 20

Cellerant Therapeutics, Inc. 21

Hospira, Inc. 22

Kiadis Pharma B.V. 23

MediPost Co., Ltd. 24

Novartis AG 25

Pharmalink AB 26

Polyphor Ltd. 27

Recoly N.V. 28

TaiGen Biotechnology Co., Ltd. 29

Targazyme, Inc. 30

TikoMed AB 31

Hematopoietic Stem Cell Transplantation - Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

Actimab-B - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

ATIR - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

BL-8040 - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

burixafor - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

busulfan liposomal IR - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

CDX-301 - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

CordSafe - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

filgrastim - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

HSC-835 - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Iomab-B - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

MultiStem - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

NecLip-G-CSF - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

POL-5551 - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

POL-6326 - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Promostem - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

romyelocel-L - Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

TM-400 - Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

TXA-127 - Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

TZ-101 - Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Hematopoietic Stem Cell Transplantation - Recent Pipeline Updates 71

Hematopoietic Stem Cell Transplantation - Dormant Projects 90

Hematopoietic Stem Cell Transplantation - Discontinued Products 91

Hematopoietic Stem Cell Transplantation - Product Development Milestones 92

Featured News & Press Releases 92

Sep 25, 2014: Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation 92

Sep 03, 2014: BioLineRx Doses First Patient for BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment 93

Jun 08, 2014: ScinoPharm to Provide Active Pharmaceutical Ingredient to F*TaiGen for Novel Stem Cell Drug 94

Jan 29, 2014: Actinium Engages Goodwin Biotechnology to Supply Iomab-B for Its Phase 3 Clinical Study 94

Dec 19, 2013: Actinium Completes Technology Transfer for Manufacturing of Its Lead Drug Candidate Iomab-B 95

Dec 18, 2013: Targazyme Reports Interim Phase I/IIa Trial Results for TZ101 96

Dec 10, 2013: Celldex's CDX-301 in Combination with Mozobil Increases Hematopoietic Stem Cell Mobilization and Results in Improved Transplantation of Mobilized Cells in Preclinical Studies; Results Presented at ASH 2013 97

Oct 03, 2013: Actinium Pharmaceuticals Announces Upcoming Webinar To Discuss Iomab-B 98

Sep 11, 2013: Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR and Study Meets Primary Objective 98

Jul 09, 2013: MultiStem Cell Therapy May Overcome Major Challenges in Organ Transplantations 99

 

Appendix 101

Methodology 101

Coverage 101

Secondary Research 101

Primary Research 101

Expert Panel Validation 101

Contact Us 102

Disclaimer 10

Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2014 9

Number of Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H2 2014 10

Number of Products under Development by Companies, H2 2014 12

Comparative Analysis by Late Stage Development, H2 2014 13

Comparative Analysis by Clinical Stage Development, H2 2014 14

Comparative Analysis by Early Stage Development, H2 2014 15

Products under Development by Companies, H2 2014 16

Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 17

Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H2 2014 18

Hematopoietic Stem Cell Transplantation - Pipeline by BioLineRx, Ltd., H2 2014 19

Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H2 2014 20

Hematopoietic Stem Cell Transplantation - Pipeline by Cellerant Therapeutics, Inc., H2 2014 21

Hematopoietic Stem Cell Transplantation - Pipeline by Hospira, Inc., H2 2014 22

Hematopoietic Stem Cell Transplantation - Pipeline by Kiadis Pharma B.V., H2 2014 23

Hematopoietic Stem Cell Transplantation - Pipeline by MediPost Co., Ltd., H2 2014 24

Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H2 2014 25

Hematopoietic Stem Cell Transplantation - Pipeline by Pharmalink AB, H2 2014 26

Hematopoietic Stem Cell Transplantation - Pipeline by Polyphor Ltd., H2 2014 27

Hematopoietic Stem Cell Transplantation - Pipeline by Recoly N.V., H2 2014 28

Hematopoietic Stem Cell Transplantation - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2014 29

Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H2 2014 30

Hematopoietic Stem Cell Transplantation - Pipeline by TikoMed AB, H2 2014 31

Assessment by Monotherapy Products, H2 2014 32

Number of Products by Stage and Target, H2 2014 34

Number of Products by Stage and Mechanism of Action, H2 2014 36

Number of Products by Stage and Route of Administration, H2 2014 38

Number of Products by Stage and Molecule Type, H2 2014 40

Hematopoietic Stem Cell Transplantation Therapeutics - Recent Pipeline Updates, H2 2014 71

Hematopoietic Stem Cell Transplantation - Dormant Projects, H2 2014 90

Hematopoietic Stem Cell Transplantation - Discontinued Products, H2 2014 91

Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2014 9

Number of Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H2 2014 10

Number of Products under Development by Companies, H2 2014 11

Comparative Analysis by Clinical Stage Development, H2 2014 14

Assessment by Monotherapy Products, H2 2014 32

Number of Products by Top 10 Targets, H2 2014 33

Number of Products by Stage and Top 10 Targets, H2 2014 34

Number of Products by Top 10 Mechanism of Actions, H2 2014 35

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 36

Number of Products by Top 10 Routes of Administration, H2 2014 37

Number of Products by Stage and Top 10 Routes of Administration, H2 2014 38

Number of Products by Top 10 Molecule Types, H2 2014 39

Number of Products by Stage and Top 10 Molecule Types, H2 2014 40